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Epidemiologic, pathophysiologic, and clinical evidences recently revealed the link 
between upper and lower airways, changing the global pathogenic view of respiratory 
allergy. The aim of this review is to highlight the strong interaction between the upper and 
lower respiratory tract diseases, in particular allergic rhinitis and asthma.
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iNTRODUCTiON
During the second century, Claudius Galenus identified the effect of the upper airway on the lower 
airway and defined the nose as a “respiratory instrument” in his work “De usu partium.” Nevertheless, 
the concept of the upper and lower respiratory passages being a continuum and forming a single 
unified airway has been highlighted only over the last 10–15 years, starting from the Allergic Rhinitis 
and its Impact on Asthma (ARIA) World Health Organization workshop (1–3).
The mechanisms of nose and lung interaction are complex, not entirely understood, and they 
have been long investigated (4). Dating back to 1919, Sluder hypothesized the existence of a nasal-
bronchial reflex (5), supported by the evidence of a similar innervation of both upper and lower 
airways (6). More recent studies have demonstrated the role of localized inflammatory changes in 
the upper and lower airways, which lead to a systemic response (7–9).
The aim of this review is to underline the strong anatomical, epidemiologic, pathophysiologic, 
clinical, and therapeutic evidences (summarized in Table  1) supporting the connection existing 
between the so-called United Airway Disease (UAD). We focus our attention on rhinitis and asthma, 
the most frequent and chronic inflammatory diseases of the upper and lower airways, presenting 
with several phenotypes.
RHiNiTiS AND ASTHMA
The term rhinitis includes several different phenotypes and the diagnosis of each of these subtypes 
is often an interesting challenge (10). It is usual to divide rhinitis in allergic rhinitis (AR) and non-
allergic rhinitis (NAR), based on allergological evaluation (10, 11). AR is a disease of the nasal 
mucous membranes, induced by an IgE-dependent inflammation after the exposure to allergens 
(12). Symptoms of AR include rhinorrhea, nasal obstruction or blockage, nasal itching, sneezing, 
and postnasal drip, which reverse spontaneously or after treatment. AR is classified based on the 
frequency of symptoms in intermittent (symptoms occurring on less than 4 days per week or for 
less than 4 weeks per year) or persistent (symptoms occurring on at least 4 days per week or for 
more than 4 weeks per year). In addition, considering the severity of symptoms, AR can be divided 
into mild (normal sleep; no impairment of daily activities, no troublesome symptoms) or moderate 
to severe (one or more of: abnormal sleep; impairment of daily activities, and severe symptoms) 
(12). On the other hand, NAR includes a group of diseases characterized by the presence of at 
least two nasal symptoms, such as pruritus, rhinorrea, obstruction, sneezing in patients who are 
TABLe 1 | The evidence and the mechanisms of nose and lung interaction.




Pathophysiologic evidence emerging biomarkers Clinical and treatment evidence
The nasal and bronchial mucosae 
consist of ciliary epithelium resting on 
a basement membrane. Beneath the 
basement membrane is the lamina 
propria, glands, and goblet cells (17, 18)
19–38% of patients 
with allergic rhinitis 
(AR) have concomitant 
asthma and 30–80% 
of asthmatics have AR 
(15, 19)
The communication between 
the upper and lower airways 
is suggested to be via a bone 
marrow- derived systemic 
inflammatory response (17)
The role of microbiome: 
children being raised on 
traditional farms have a much 
lower prevalence of allergic 
disease as children grown up 
in urban settings (15, 18)
The treatment of AR can improve 
asthma symptoms (15, 18)
Both act as a transport system moving 
air in and out of the lungs (16)
The presence of epithelial 
basement membrane 
thickening, the typical 
hallmark of lower airway 
remodeling, not only in 
asthmatic patients but also 
in atopic patients without 
asthma and patients with 
AR (24)
The role of microRNA 
(miRNA): presence of the 
same particular miRNAs 
in different pathogenetic 
mechanisms of both AR 
and asthma, such as IL-13 
pathway, GATA binding 
protein 3, and mucin 
secretion (42)
Decrease in asthma symptoms and 
AR after intranasal corticosteroid 
treatment of rhinitis (41)
Both provide defense against inhaled 
foreign substances, with most particles 
of 5–10 μm diameter filtered out by 
the nose, and irritant and soluble 
gases being extensively removed by 
dissolution in nasal secretions. The 
lower airway functions similarly, with 
smaller inhaled particles that reach the 
lower airway being trapped and cleared 
by the mucociliary escalator (19)
In non-allergic asthma it 
has been highlighted the 
importance of the presence of 
IgE in the bronchial mucosa, 
as in the nasal mucosa in 
local allergic rhinitis (10)
Leukotriene receptor antagonists 
are known to be useful for long-term 
management of asthma patients 
complicated by AR (42)
The recombinant, humanized, 
monoclonal anti-IgE antibody 
Omalizumab improved nasal and 
bronchial symptoms and reduced 
unscheduled visits due to asthma (45)
Allergen immunotherapy is effective for 
treating both rhinitis and asthma (38)
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not sensitized to any allergen. The diagnosis is mainly based on 
exclusion (11). In the last few years, a new phenotype called local 
allergic rhinitis (LAR) has been defined (13). It is characterized 
by symptoms suggestive of AR due to a localized allergic response 
in the nasal mucosa, in the absence of atopy assessed by conven-
tional diagnostic tests. The immunological characteristics of LAR 
are nasal Th2 allergic inflammation, with positive response to 
nasal allergen provocation test, and nasal production of IgE and 
inflammatory mediators (14). However, a better understanding 
of the underlying immune mechanisms of this disease is essential 
for developing diagnostic methods and targeted therapies.
According to the recent GINA guidelines, asthma is a chronic 
disease, potentially serious, characterized by a reversible airway 
obstruction, chronic airway inflammation, and bronchial hyper-
reactivity (15). It is diagnosed by the pattern of respiratory symp-
toms, such as wheeze, chest tightness, dry cough, and shortness 
of breath, that vary over time and in intensity, together with 
variable expiratory airflow limitation, induced by the broncho-
constriction, and morphological changes in the bronchial wall 
(“remodeling”). Symptoms are usually worse during the night or 
upon awakening, and the principal triggers are viral infections, 
allergens, tobacco smoke, exercise, and stress (15).
ANATOMiCAL eviDeNCe
Anatomically, the respiratory tree is divided into upper (nose, 
pharynx, and larynx) and lower respiratory tract (trachea, bron-
chi, bronchioles, alveolar duct, and alveoli), separated by the lar-
ynx. Functionally, it is divided between conductive airways and 
gas-exchange region of the lungs, consisting of the respiratory 
bronchioles with the air cells (16). Although in daily practice, the 
nose and the lungs are considered as separate entities and treated 
by two different specialists, the upper and the lower respiratory 
tracts have anatomical and histological similarities, including the 
basement membrane, lamina propria, ciliary epithelium, glands, 
and goblet cells (17, 18). Moreover, both allow the passage of air 
into and out of the lungs and during inspiration the air is humidi-
fied, tempered, filtered, and supplied with nitric oxide before 
entering the lower airways. Nasal airconditioning capacities and 
filter function protect the lower airways from potentially harmful 
agents and it also participates to innate and adaptive immune 
defense (16). Patients with AR have partial or complete loss of 
function of the nose due to mucosal congestion and in this case 
the inhalation of cold or dry air can favor bronchoconstriction 
(19). Moreover, the nose protects the lower tract from inhaled 
FiGURe 1 | Macroscopic pathological characteristics.
FiGURe 2 | Histological appearance.
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foreign substances by filtering out the particles of 5–10  μm 
diameter, while the irritant and soluble gases are extensively 
removed by dissolution in nasal secretions (19). The lower air-
way acts similarly: the smaller inhaled particles are trapped and 
cleared by the mucociliary escalator (19). Furthermore, in case 
of disease, they share macroscopic pathological characteristics 
(Figure 1) and also the histological appearance is similar, with a 
comparable allergic response in rhinitis and asthma (Figure 2). 
The main difference between the nose and the lungs is that 
upper airway obstruction is mainly caused by vasodilatation 
and edema, whereas the lower airway patency is influenced by 
smooth muscle function.
ePiDeMiOLOGiC eviDeNCe
Asthma and rhinitis are a major public health problem because 
of their frequency, their impact on quality of life, school 
performance, and economic burden (1). The influence on 
patients’ quality of life has also been highlighted by a recent 
study on 2,896 children enrolled in the Taiwan Children Health 
Study, which demonstrated an association between allergic 
diseases, such as asthma and AR, and deficit hyperactivity 
disorder and oppositional defiant disorder (20). According to 
the International Study on Asthma and Allergy in Childhood, 
the prevalence of asthma worldwide was found to be 20%, 
and the prevalence of AR in Europe was observed to be 25% 
(1). Moreover, the prevalence of asthma and rhinitis varies all 
over the world: in countries with a more rural tradition, the 
numbers are usually lower than in countries with a higher level 
of urbanization (15, 19). Interestingly, the prevalence of asthma 
in subjects without rhinitis is usually less than 2% (17). The 
prevalence of AR appears to be at least triple the prevalence 
of asthma, and it has also been demonstrated that 19–38% of 
patients with AR have concomitant asthma and 30–80% of 
asthmatics have AR (15, 19).
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PATHOPHYSiOLOGiC eviDeNCe
Allergic UAD
An immune response to external antigens induces the produc-
tion of antibodies that are typically, but not exclusively, IgE 
antibodies. Allergic airway disease is caused by hypersensitivity 
or IgE-mediated reactions when inhaled allergen reacts with 
mast cells and basophils, the major effector cells, bearing IgE 
antibodies. The following cross-linking of allergen-specific 
IgE molecules bound to cells by allergen particles, results in 
the release of granule-associated mediators (i.e., histamine, 
tryptase), membrane lipid-derived mediators (i.e., leukotrienes), 
and cytokines (15, 20). Over time, the role of lipids in the patho-
genesis of allergic disease has continued to expand thanks to 
sophisticated techniques capable of identifying and quantifying 
diverse lipid mediators (21). The early allergic response (maximal 
at 10–20 min) is usually characterized by edema, itching in the 
skin, rhinorrhea, sneezing, and erythema in the upper airways 
and bronchospasm, edema, mucous secretion, and cough in the 
lower respiratory tract. Instead, the late allergic response (within 
2–6 h) in both the upper and lower airways is associated with an 
eosinophil activation and CD4 T cell tissue infiltrate, essential to 
maintain the chronic inflammatory process and tissue damage 
(20, 22).
To explain the interaction between the upper and lower air-
ways, several mechanisms have been suggested (1, 16). The most 
likely mechanism is that localized inflammatory changes in the 
upper and lower airways leads to a systemic response, with bone 
marrow involvement, resulting in the release of progenitor cells 
that are then recruited to tissue sites. Inflammatory secretions may 
propagate from the upper airways to the lower via postnasal drip 
and systemic circulation. Although the nose is usually the first 
site of exposure to allergens or other noxious substances, despite 
a minimal nasal epithelial damage, a marked bronchial epithelial 
disruption may be present. Hence, researches hypothesized that 
the nasal mucosa has developed protective mechanisms that 
minimize remodeling and enhance epithelial regeneration (23). 
An important proof of the UAD interplay is the presence of epi-
thelial basement membrane thickening, the typical hallmark of 
lower airway remodeling, not only in asthmatic patients but also 
in atopic patients without asthma and patients with AR. However, 
remodeling appears to be less extensive in the nasal mucosa than 
in the bronchial mucosa. The reason of this difference could be 
explained by the specific cytokine production of smooth muscle 
cells and by the presence of the genes of the embryologic dif-
ferentiation in the nose and lungs or their different re-expression 
in asthma and rhinitis (24).
Non-Allergic UAD
In contrast to allergic UAD, the etiology and mechanisms involved 
in non-allergic UAD is still unknown. In non-allergic asthma, it 
has been highlighted the importance of the presence of IgE in the 
bronchial mucosa, as in the nasal mucosa in LAR (10). However, 
it is still not clear what is the role of allergens in the asthmatic 
symptoms in patients with LAR. Some of the possibilities include 
allergy triggered by unknown antigens (fungi), persistent 
infection (caused by Chlamydia trachomatis, Mycoplasma spp., 
or viruses), and autoimmunity (10).
RiSK FACTORS
Allergen exposure
The allergen exposure has been considered the major risk fac-
tor for the development of UAD (15, 18). Rhinitis and asthma 
are characterized by a high prevalence of sensitization to those 
allergens that are common in the community, i.e., aeroallergens. 
When considering different aero/inhaled allergens, the most 
important distinction is that between outdoor allergens (i.e., 
pollen and molds), indoor allergens (i.e., cat, dog, mite), and 
occupational agents. Nevertheless, there are still important 
questions about the relevance of current allergen exposure to 
these diseases and to their management. Different factors can 
influence the IgE antibody response including genetics, allergen 
dose, and early life exposures that may inhibit or enhance the 
response (25).
Genetic Factors
It is well known that allergic diseases run in families, implying a 
role for genetic factors in determining individual susceptibility: 
hereditability varies from 35 to 95% for asthma and from 33 to 
91% for AR (26). Studies on the prevalence of allergic traits in 
relation to family history demonstrated incremental increases in 
risk of developing asthma or AR with the presence of one or both 
parents with allergic disease, and greater than three times the risk 
if allergic disease occurred in more than one first degree relative 
(26). To date, a positive family history remains one of the most 
reliable tools for prognosis of allergic disease (27). Moreover, the 
Multicentre Allergy Study has demonstrated that having parents 
with allergies is not only a strong predictor to develop any 
allergy but also strongly increases the risk of developing allergic 
multi-morbidity (28). A link of asthma and AR with different 
chromosomal regions was recently found thanks to genome-wide 
association studies. Actually, there are about 161 different poten-
tial biomarkers involved in respiratory inflammation (26). For 
example, Liu et al. have recently shown that the single-nucleotide 
polymorphisms in the TNFSF4 and FAM167A-BLK genes may 
be involved in asthma and AR gene (29) and Zhao et al. associated 
the PBX2 gene in the 6p21.3 asthma susceptibility locus with an 
increased risk for both AR and asthma (30). The genetic studies 
of allergic disease pave the way for tailored treatments to specific 
genotypes to improve therapeutic outcomes and minimize side 
effects.
Other Risk Factors
Environmental exposures during pregnancy including diet, 
nutrient intake (especially vitamin D) (31), toxins (smoking, 
air pollution, microbes, infection) can alter the epigenome 
and interact with inherited genetic and epigenetic risk factors 
to directly and indirectly influence organ development and 
immune programming (32). Considering these data, the pri-
mary prevention of allergic disease should begin very early in 
life, even in utero (25).
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eMeRGiNG BiOMARKeRS
The Role of Microbiome
Microbiome is the totality of microbes, their genes, and their interac-
tions in a given environment. It is increasingly accepted that human 
microbiome may play an important role by promoting the matura-
tion of the host immune system. Thanks to advances in sequencing 
technologies, such as real-time quantitative PCR, it is now known 
that the microbes that inhabit healthy and diseased nose and lungs 
are different (33). According to the “hygiene hypothesis,” microbial 
exposures in early childhood may prevent allergies and asthma 
by modulating the Th1/Th2 and Treg imbalance (33). As matter 
of fact, children being raised on traditional farms have a much 
lower prevalence of allergic disease as children grown up in urban 
settings. The diversity of the microbial exposure has been shown 
to account for the asthma-protective farm effect. Nevertheless, in 
urban areas high exposure to environmental microbes also relates 
to a lower prevalence of allergic disease (15, 18). So, the microbiome 
itself could be considered as a potential biomarker source. A recent 
study demonstrated an association of asthma with reduced α- and 
β-diversity of the nasal microbiota and the relative abundance of a 
bacteria belonging to the genus Moraxella. The linking of asthma 
and Moraxella, however, was restricted to children not living on 
farms. In contrast to the nasal samples, the throat microbiota 
characteristics were not related to asthma (34).
The Role of microRNA (miRNA)
microRNAs, a recently discovered regulators of gene expres-
sion, might be another non-invasive biomarkers to diagnose 
and characterize asthma and allergic. Circulating miRNAs have 
been considered to be involved in many inflammatory diseases, 
although gene regulation in the common inflammatory processes 
in UAD remains unclear (35). Panganiban et  al. identified 30 
miRNAs that were differentially expressed among healthy, aller-
gic, and asthmatic subjects. These miRNAs fit into five different 
expression pattern groups. Among asthmatic patients, miRNA 
expression profiles identified two subtypes that differed by high 
or low peripheral eosinophil levels. Circulating miR-125b, miR-
16, miR-299-5p, miR-126, miR-206, and miR-133b levels were 
most predictive of allergic and asthmatic status (35). These find-
ings have shown the presence of the same particular miRNAs in 
different pathogenetic mechanisms of both AR and asthma, such 
as IL-13 pathway, GATA-binding protein 3, and mucin secretion. 
Interestingly, recent studies have shown that miRNAs could be 
used as potential pharmaceutical targets for anti-inflammatory 
treatment (36).
CLiNiCAL AND TReATMeNT eviDeNCe
The interaction between nose and lung in allergic airways 
disease is a bidirectional process, indeed it has been proved 
that the treatment of AR can improve asthma symptoms (15, 
18). Subsequent ARIA updates and other reviews have made 
an attempt to summarize the diagnostic and therapeutic 
implications of this link based on these published evidence, 
but the evidence is still far from conclusive, due to limited 
number of randomized controlled trials available on subjects 
with concomitant AR and asthma (15, 18). Therapy for UAD 
is based on avoidance of the main allergens and irritants and 
pharmacotherapy [nasal and inhaled steroids, antihistamines, 
leukotriene receptor antagonists (LTRA), anti-IgE therapy, and 
allergen immunotherapy (AIT)] (11).
Allergen Avoidance
Once allergy testing is complete, the physician may devise a 
comprehensive program of allergen avoidance. The lack of hay 
fever outside the pollen season indicates that complete allergen 
avoidance can be effective. Unfortunately, complete avoidance 
is rarely possible, especially for outdoor allergens. The effects of 
environmental control strategies have been most heavily studied 
with regard to dust mites and furry pets (37). Compliance with 
these measures may be difficult but will certainly be helpful in 
many patients with hypersensitivity to these allergens. Avoidance 
of other rhinitis and asthma triggers, such as cigarette smoke, 
outdoor pollutants, fumes, and irritants, is sensible in clinical 
practice (38).
Pharmacologic Therapy
Oral and/or intranasal antihistamines and nasal corticosteroids are 
both appropriate for first-line AR treatment although the latter are 
more effective (39, 40).
Some authors reported a decrease in asthma symptoms and 
AR after intranasal corticosteroid treatment of rhinitis and a 
recent meta-analysis confirmed the beneficial effect of intrana-
sal steroids in AR (41). LTRAs are known to be useful for long-
term management of asthma patients complicated by AR (42). 
Leukotrienes are generated by the metabolism of arachidonic 
acid via the 5-lipoxygenase (5-LO) pathway, which is involved 
in the rapid initial inflammation response. LTRAs block the 
cysteinyl-leukotriene receptor, which are peptide-conjugated 
lipids produced by activated basophils, eosinophils, mast cells, 
and macrophages, to relieve the symptom of AR (42). Recent 
studies demonstrated that LTRAs have a significant influence in 
improving patients’ nasal symptoms and quality of life and the 
use of LTRAs in combination with antihistamines has generally 
resulted in greater efficacy than when these agents were used 
alone (43). The recombinant, humanized, monoclonal anti-IgE 
antibody (Omalizumab) forms complexes with free IgE, block-
ing its interaction with mast cells and basophils and lowering 
free IgE levels in the circulation (44). Omalizumab has been 
tested in several clinical trials, and its beneficial effect has 
been established in patients with uncontrolled allergic asthma, 
leading to its approval by FDA (38). In patients with severe 
asthma and rhinitis, omalizumab improved nasal and bronchial 
symptoms and reduced unscheduled visits due to asthma. The 
clinical benefit of treatment with omalizumab is associated with 
an anti-inflammatory effect on cellular markers in blood and 
nasal tissue, as well as with a reduction in FcRI expression and 
function (45).
The only treatment potentially able to interfere with the 
natural history of respiratory allergy is AIT, specifically aimed 
at modifying the response to sensitizing allergens (37). Current 
data support the effectiveness of AIT in AR and a beneficial 
effect in allergic asthma (38). In particular, AIT may prevent 
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the onset of asthma by halting the progression from rhinitis, 
by preventing new sensitizations or by avoiding the primary 
development of allergy (46). In the context of the UAD, AIT 
consistently shows a clear benefit for both the upper and the 
lower airways.
CONCLUSiON
The link between upper and lower airways, the so-called UAD, 
has been revealed by several epidemiologic, pathophysiologic, 
and clinical evidences, changing the global pathogenic view of 
respiratory allergy. AR and asthma are both manifestations of a 
single inflammatory process and require an integrated diagnostic 
and therapeutic approach in order to get global disease control.
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